{"title": "An Effective CTL Peptide Vaccine for Ebola Zaire Based on Survivors\u2019 CD8+ Targeting of a Particular Nucleocapsid Protein Epitope with Potential Implications for COVID-19 Vaccine Design", "doi": "10.1101/2020.02.25.963546", "citation_id": "2020.02.25.963546v3", "date": "2020-03-09", "laguage": "en", "journal_title": "bioRxiv", "first_page": "2020.02.25.963546", "abstract": "<p>The 2013-2016 West Africa EBOV epidemic was the biggest EBOV outbreak to date. An analysis of virus-specific CD8+ T-cell immunity in 30 survivors showed that 26 of those individuals had a CD8+ response to at least one EBOV protein. The dominant response (25/26 subjects) was specific to the EBOV nucleocapsid protein (NP). It has been suggested that epitopes on the EBOV NP could form an important part of an effective T-cell vaccine for Ebola Zaire. We show that a 9-amino-acid peptide NP44-52 (YQVNNLEEI) located in a conserved region of EBOV NP provides protection against morbidity and mortality after mouse adapted EBOV challenge. A single vaccination in a C57BL/6 mouse using an adjuvanted microsphere peptide vaccine formulation containing NP44-52 is enough to confer immunity in mice. Our work suggests that a peptide vaccine based on CD8+ T-cell immunity in EBOV survivors is conceptually sound and feasible. Nucleocapsid proteins within COVID-19 contain multiple class I epitopes with predicted HLA restrictions consistent with broad population coverage.  A similar approach to a CTL vaccine design may be possible for that virus.</p>", "twitter_description": "The 2013-2016 West Africa EBOV epidemic was the biggest EBOV outbreak to date. An analysis of virus-specific CD8+ T-cell immunity in 30 survivors showed that 26 of those individuals had a CD8+ response to at least one EBOV protein. The dominant response (25/26 subjects) was specific to the EBOV nucleocapsid protein (NP). It has been suggested that epitopes on the EBOV NP could form an important part of an effective T-cell vaccine for Ebola Zaire. We show that a 9-amino-acid peptide NP44-52 (YQVNNLEEI) located in a conserved region of EBOV NP provides protection against morbidity and mortality after mouse adapted EBOV challenge. A single vaccination in a C57BL/6 mouse using an adjuvanted microsphere peptide vaccine formulation containing NP44-52 is enough to confer immunity in mice. Our work suggests that a peptide vaccine based on CD8+ T-cell immunity in EBOV survivors is conceptually sound and feasible. Nucleocapsid proteins within COVID-19 contain multiple class I epitopes with predicted HLA restrictions consistent with broad population coverage. A similar approach to a CTL vaccine design may be possible for that virus.", "full_text_html_url": "https://www.biorxiv.org/content/10.1101/2020.02.25.963546v3.full", "public_url": "https://www.biorxiv.org/content/10.1101/2020.02.25.963546v3", "abstract_html_url": "https://www.biorxiv.org/content/10.1101/2020.02.25.963546v3.abstract", "pdf_url": "https://www.biorxiv.org/content/biorxiv/early/2020/03/09/2020.02.25.963546.full.pdf", "rights": "\u00a9 2020, Posted by Cold Spring Harbor Laboratory. The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission.", "publisher": "Cold Spring Harbor Laboratory", "pisa": "biorxiv;2020.02.25.963546v3", "access_rights": "restricted", "authors": ["CV Herst", "S Burkholz", "J Sidney", "A Sette", "PE Harris", "S Massey", "T Brasel", "E Cunha-Neto", "DS Rosa", "WCH Chao", "R Carback", "T Hodge", "L Wang", "S Ciotlos", "P Lloyd", "R Rubsamen"]}